PURPOSE: Topical prostaglandin analogs such as latanoprostene bunod (LBN) are indicated for the reduction of intraocular pressure (IOP). This study aims to document real-world outcomes, utilization patterns, and eyecare practitioner (ECP) satisfaction with LBN in patients with open-angle glaucoma or ocular hypertension.

METHODS: This retrospective, multicenter, cross-sectional case review and survey study included licensed ophthalmologists/optometrists with ≥3 years' experience who had prescribed LBN ophthalmic solution 0.024% in ≥10 patients in the last 12 months. ECPs submitted deidentified cases via a standardized case report form and completed a prescriber's experience survey. Outcomes included IOP and safety. The protocol received central institutional review board exemption.

RESULTS: This interim analysis included 85 eyes (56 patients; 55% female; mean±SD age, 68±15 years) from five sites in the USA. Overall, 71% (39/55; n=1 unknown) had ocular comorbidities. At baseline, the mean±SD IOP (n=83) and target IOP (n=78) were 19.9±6.5 and 14.5±2.4 mmHg, respectively. At most recent follow-up, 89% (48/54; n=2 unknown) of patients remained on LBN treatment. The median (interquartile range) time since treatment initiation was 28 (12–51) weeks. At most recent follow-up, mean±SD IOP was 14.3±5.6 mmHg, representing a 28% decrease from baseline (N=85 eyes). Eleven adverse events were reported in nine patients; the most common was a decrease in visual acuity. Of five ECPs surveyed, four were from a medium-sized practice (11–50 ECPs); all ECPs had ≥11 years' experience. ECPs rated LBN effectiveness (mean±SD) as 9.2±0.5 and 8.0±1.9 for eyes with no prior treatment and with previous failed IOP-lowering drops, respectively (on a scale from 0, very poor effectiveness, to 10, very good effectiveness). ECPs ranked their overall satisfaction with LBN as a mean±SD of 9.2±0.5 (on a scale from 0, very dissatisfied, to 10, very satisfied).

CONCLUSIONS: LBN 0.024% ophthalmic solution was clinically effective in this real-world study, with patients showing decreased IOP. ECPs reported high clinical effectiveness and satisfaction with this treatment.